# DAPA-CKD: dapagliflozin in chronic kidney disease

Study · id `cardio:dapa-ckd` · Cardiovascular Atlas · release `5dcd9b263fe17744` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: DAPA-CKD

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A large trial of people with chronic kidney disease, with or without type 2 diabetes. Half took dapagliflozin 10 mg a day and half took placebo. The monitoring committee recommended stopping the trial early because dapagliflozin was working. It lowered the risk of kidney failure, a large fall in kidney function, or death from a kidney or heart cause, and the effect was similar with and without diabetes.

## Technical summary

Randomized, double-blind, placebo-controlled trial sponsored by AstraZeneca (NCT03036150). 4304 participants with an eGFR of 25 to 75 and a urinary albumin-to-creatinine ratio of 200 to 5000. Median follow-up 2.4 years. Primary outcome (sustained eGFR decline of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes): 197 of 2152 (9.2%) against 312 of 2152 (14.5%), hazard ratio 0.61 (95% CI 0.51 to 0.72; P<0.001).

## Key facts

- Design: Randomized, double-blind, placebo-controlled, parallel-group trial. The registry records phase 3 and quadruple masking.
- Phase: Phase 3
- Enrolled: 4304 participants (enrolled count; A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease, snapshot `cardio:ctgov-nct03036150-2026-10-14`, retrieved 2026-10-14)
- Started: 2017-02-02 (actual) (A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease, snapshot `cardio:ctgov-nct03036150-2026-10-14`, retrieved 2026-10-14)
- Primary completion: 2020-06-12 (actual) (A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease, snapshot `cardio:ctgov-nct03036150-2026-10-14`, retrieved 2026-10-14)
- Completion: 2020-06-12 (actual) (A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease, snapshot `cardio:ctgov-nct03036150-2026-10-14`, retrieved 2026-10-14)
- Results first posted: 2021-07-07 (actual) (A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease, snapshot `cardio:ctgov-nct03036150-2026-10-14`, retrieved 2026-10-14)
- Countries: United States; Argentina; Brazil; Canada; China; Denmark; Germany; Hungary; India; Japan; Mexico; Peru; Philippines; Poland; Russia; South Korea; Spain; Sweden; Ukraine; United Kingdom; Vietnam (A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease, snapshot `cardio:ctgov-nct03036150-2026-10-14`, retrieved 2026-10-14)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), snapshot `cardio:ctgov-nct03036150-2026-10-14`, retrieved 2026-10-14)
- Stopped early: The trial stopped early, date not reported. The independent data monitoring committee recommended stopping the trial because of efficacy. The registry records the study as completed. (Dapagliflozin in Patients with Chronic Kidney Disease, snapshot `cardio:pubmed-32970396-2026-10-14`, retrieved 2026-10-14)

## Connected pages

- Lists chronic kidney disease as its condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Lead sponsor on the registry record: AstraZeneca (`cardio:astrazeneca`)
- Tests this medicine: Dapagliflozin (`cardio:dapagliflozin`)
- Names a sustained eGFR decline in its primary outcome: Estimated glomerular filtration rate (eGFR) (`cardio:egfr`)

## Provenance

Content hash: ba3a65752a52aa2247d9e2c08502216003cc6ce2ad77f783fb43ab860b64f3e6
Last substantive edit: 2026-10-15
Evidence last checked: Not recorded